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SUMMARY
Polymyalgia rheumatica (PMR) is the commonest inflammatory rheumatic disease affecting older people. The 
current mainstay of treatment is long-term oral glucocorticoid therapy. Management of these patients in clinical 
practice is often complicated by the presence of comorbidity. Comorbidity might be due to shared risk factors 
such as age, sex, or genetic background; to the presence of the disease itself; or to adverse effects of gluco-
corticoid therapy. Cardiovascular disease, osteoporosis/fracture, metabolic and ocular comorbidity are of par-
ticular interest to clinicians because of their relationship to glucocorticoid therapy and the relevance to clinical 
treatment decisions regarding glucocorticoid tapering. Patients at high risk of exacerbation of comorbidity by 
glucocorticoid therapy may be considered for adjunctive steroid-sparing therapies and thus may need specialist 
management. From a public health perspective, with the ageing population the prevalence of PMR is predicted 
to increase; accurate data on comorbidity will be needed for planning and delivery of healthcare services.
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n	 INTRODUCTION
Polymyalgia rheumatica (PMR) presents with pain and stiffness of the shoulder 
and hip girdles in association with elevated 
laboratory markers of inflammation (1). 
The incidence of PMR is highest in the 
eighth decade of life; PMR is classically 
said not to occur under the age of 50 years. 
PMR may occur together with giant cell ar-
teritis (GCA), a vasculitis of large and me-
dium sized blood vessels (2, 3). There is no 
single diagnostic test for confirmation of 
PMR; other rheumatic conditions such as 
rheumatoid arthritis may sometimes pres-
ent with similar features but the correct di-
agnosis usually emerges during follow-up 
(4-6). A systemic inflammatory response 
and arthralgia may also be the presenting 
feature of many other medical conditions, 
including cancer (7, 8). A challenge of in-
terpretation of the current literature is the 
relative paucity of research literature com-
pared to many other rheumatic diseases. 
Additionally, many early reports in the 
literature did not clearly distinguish well 
between PMR and GCA.
Patients with PMR and no evidence of oth-
er rheumatic disease are generally treated 
with long-term oral glucocorticoids (GC) 
such as prednis(ol)one. The starting dose 
is 15-25 mg of prednisone equivalent; this 
dose is gradually tapered over 1-2 years 
with an aim to stopping (9). Some patients 
however require ongoing GC therapy for 
many more years. There is some limited 
evidence for methotrexate as a steroid-
sparing drug (10). Older patients are par-
ticularly vulnerable to GC-related adverse 
effects, particularly where their baseline 
risk is already high due to pre-existing co-
morbidities. 
Comorbidity in patients with PMR remains 
a significant issue in clinical management 
of individual patients with PMR, as well 
as being relevant to understanding the 
overall burden of this disease and its treat-
ment within the general population. Recent 
clinical practice guidelines recommend 
assessment for comorbidity in all patients 
presenting with PMR (11). Comorbidity 
is important to establish in inflammatory 
rheumatic diseases because of increased 
prevalence of comorbid conditions com-
pared to the general population (especially 
as a consequence of GC therapy), issues 
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of equity (patients with chronic rheumatic 
diseases should have the same opportu-
nities for health promotion/screening as 
people from the general population who do 
not have rheumatic disease) and the poten-
tial impact of comorbidities on outcomes 
of treatment of the rheumatic disease itself 
(12). In this review, we survey comorbid 
conditions that may be associated with 
PMR and those conditions which are par-
ticularly important for making decisions 
about continuing treatment.
Co-occurence of polymyalgia rheumatica 
with giant cell arteritis
GCA is associated with PMR in that the 
two conditions co-exist more frequently 
than would be expected by chance. The de-
mographics of the two diseases are similar: 
older age, female sex, and northern Euro-
pean ancestry are risk factors for both PMR 
and GCA. Both PMR and GCA are charac-
terised by a systemic inflammatory response 
which responds to systemic GC therapy (3, 
13). The two conditions may either present 
at the same time or may sometimes be sepa-
rated by long intervals; when presenting on 
different occasions, either one may present 
before the other (14). It has been postulated 
that both conditions may share a common 
genetic background. GCA has a strong as-
sociation with genes within the major histo-
compatibility complex region (MHC) but as 
yet there are no large-scale studies of MHC 
associations in PMR (15-17).
Case reports and case series using modern 
imaging modalities such as positron emis-
sion tomography with low-dose CT (PET/
CT) suggest that some patients apparently 
presenting with clinical features of isolated 
PMR additionally have inflammation of the 
aorta and proximal branches. This large-
vessel GCA may not be clinically evident 
without vascular imaging. Most case se-
ries report that polymyalgic symptoms 
are present in around half of patients diag-
nosed with GCA; in many cases the poly-
myalgic symptoms are the first symptom 
and the patient may be initially treated as 
isolated PMR before the more characteris-
tic features of GCA appear (2).
The prevalence of subclinical GCA in pa-
tients presenting with the clinical picture 
of PMR cannot be accurately determined 
without prospective vascular imaging stud-
ies; the prevalence of large-vessel GCA in 
patients with PMR is likely to be higher in 
patients recruited from specialist care than 
those diagnosed with PMR in the commu-
nity. Estimates of the prevalence of GCA in 
patients with PMR can be as high as 21%; 
patients with PMR and concomitant GCA 
may be older and have higher acute-phase 
markers in comparison with those with 
PMR and no GCA (6, 14, 18).
Polymyalgic symptoms as a presenting 
feature of other rheumatic diseases
Due to the non-specific nature of poly-
myalgic symptoms, other inflammatory 
rheumatic diseases may often be initially 
diagnosed as PMR (19). Rheumatoid ar-
thritis (which in this age group is some-
times called late-onset rheumatoid ar-
thritis or LORA) may frequently present 
with features identical to PMR; the char-
acteristic swelling of the small joints may 
only manifest as the GC dose is tapered 
over the first year (20). With the advent 
of modern diagnostic imaging in routine 
clinical practice it has been proposed that 
imaging may help identify other inflam-
matory rheumatic diseases at an early 
stage, before starting GC treatment (21). 
Further studies are required to formally 
test this idea.
Polymyalgic symptoms as a presenting 
feature of malignancy
Malignancy can present with PMR-like 
symptoms (22); epidemiological studies 
are contradictory (7, 23, 24) but there is 
some evidence for an increase in cancer 
diagnoses following a diagnosis of PMR, 
particularly during the first six months fol-
lowing the PMR diagnosis (25). Prior to 
this, there were a few case reports of PMR 
occurring in patients with malignancy; it 
has been suggested that clinicians might 
have a higher index of suspicion for ma-
lignancy in patients with atypical features 
of PMR such as absence of prolonged 
morning stiffness, non-response to GC 
and/or absence of typical PMR imaging 
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findings (26). In a systematic review and 
meta-analysis, Ungprasert et al. reported a 
slightly elevated malignancy risk among 
patients with GCA/PMR, with a higher 
risk for malignancy during the first year 
after the diagnosis of PMR. However, it 
should be noted that in some of the stud-
ies included in this meta-analysis, it was 
difficult to separate out patients with iso-
lated PMR from those with a diagnosis of 
GCA in addition to PMR. Furthermore, 
the authors’ funnel plot suggested the 
possibility of publication bias. One of the 
studies included in the meta-analysis only 
included hospitalized patients, potentially 
introducing a selection bias; if the study 
restricted to hospitalized cases was ex-
cluded from the analysis, statistical sig-
nificance of the pooled risk ratio was lost 
(27). It has been recently proposed that 
older age, male sex and more extensive 
joint involvement should be considered as 
potential red flags for cancer in PMR (28). 
In nationwide registry studies, patients 
with PMR appeared to be at elevated risk 
for lymphoma, both for Hodgkin’s and 
non-Hodgkin’s lymphoma overall (8, 29) 
as well as for some subtypes of haemato-
logical malignancy (30, 31).
Comorbidity associated with prior 
glucocorticoid exposure
Comorbidity in PMR may be particularly 
important where patients have already had 
extensive prior exposure to GC, for exam-
ple patients with long-standing chronic 
respiratory disease (such as asthma, bron-
chiectasis or chronic obstructive pulmo-
nary disease) requiring multiple previous 
courses of oral GC over the years prior to 
their diagnosis of PMR. Many GC-related 
adverse events are related to cumulative 
dose of GC; osteoporosis, for example, 
is common in patients who have been 
treated with GC for chronic respiratory 
disease. If the baseline fracture risk be-
fore PMR is already high, then adding in 
long-term GC for the PMR may lead to a 
high absolute fracture risk. Such patients 
may need careful management to mini-
mize the cumulative dose of GC required 
for their PMR. 
Glucocorticoid-related adverse events in 
polymyalgia rheumatica
Case series and disease cohorts of patients 
with PMR reveal a high incidence of glu-
cocorticoid-related adverse events includ-
ing osteoporosis, fracture, diabetes, weight 
gain, hypertension, diabetes, myocardial 
infarction and stroke (32-37). This in itself 
is important for making treatment deci-
sions regarding adjustment of GC therapy, 
or commencement steroid sparing therapy, 
in PMR. However, without some compari-
son to controls without PMR, these study 
designs do not necessarily indicate an el-
evated risk of these adverse events in in-
dividuals with PMR over and above indi-
viduals without PMR of the same age and 
sex. Well-powered studies involving com-
parison to population-based controls have 
been conducted in regard to certain of these 
comorbidities, notably cardiovascular dis-
ease and osteoporosis. 
Cardiovascular disease as a comorbidity 
in polymyalgia rheumatica
It has been hypothesised that, like other 
inflammatory rheumatic diseases such as 
RA and ankylosing spondylitis, PMR may 
be associated with cardiovascular disease 
due to accelerated atherosclerosis. There 
are various plausible biological mecha-
nisms by which systemic inflammation 
may cause endothelial dysfunction and/or 
drive accelerated atherosclerosis. Although 
endothelial dysfunction can be studied ex-
perimentally (38) and does appear to be 
associated with untreated PMR, epidemio-
logical studies are required to test whether 
treated PMR is associated with an excess 
of cardiovascular disease/cardiovascular 
events, and whether any association per-
sists after controlling for traditional cardio-
vascular risk factors. Here, GC treatment is 
a complicating factor; although GC ther-
apy may control the systemic inflamma-
tion, GC excess (Cushing’s syndrome) is a 
known cause of accelerated cardiovascular 
disease (39, 40). Cushing’s syndrome is as-
sociated with an increased risk of hyperten-
sion, diabetes and dyslipidaemia.
The absolute risk of cardiovascular disease 
attributable to GC therapy in rheumatic dis-
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ease remains somewhat controversial (41). 
According to a recent systematic review 
an association between PMR and vascular 
disease was reported by some studies, but 
this was more commonly reported in ret-
rospective studies compared to prospective 
studies (42). A meta-analysis suggested a 
significantly elevated risk ratio for coro-
nary artery disease in patients with PMR 
compared to patients without PMR; how-
ever, high statistical heterogeneity between 
studies was identified so this pooled risk 
ratio must be interpreted with caution (43).
There may be an increased risk of subse-
quent stroke in patients with PMR com-
pared to patients without PMR (44, 45). 
Two different studies of patients without 
cardiovascular disease from the UK re-
ported divergent findings regarding risk of 
cardiovascular disease following PMR di-
agnosis (46, 47); this difference in findings 
may relate to differences in the datasources 
used as well as potential differences in 
coding and different statistical analyses. 
At present, therefore, due to limitations of 
currently available data it remains unclear 
whether treated PMR is associated with an 
elevated long-term cardiovascular risk. 
Osteoporosis as a comorbidity  
in polymyalgia rheumatica
Fragility fracture is a well-known risk of 
long-term GC therapy. This is particularly 
evident for prednis(ol)one doses >5 mg per 
day (48). Fracture risk appears to relate 
both to the daily dose and to the overall 
duration of GC treatment. It has been sug-
gested that the highest fracture risk in PMR 
is during the first six months of therapy, 
when the GC dose is highest (49); howev-
er, in other studies the fracture risk appears 
greatest after prolonged therapy, indicating 
the importance of treatment duration (33). 
In a meta-analysis, Hoes et al. reported that 
higher dosages of GCs resulted in higher 
adverse event rates in studies of PMR of 
comparable quality (50). In a recent mul-
ticentre study, Rossini et al. noted that fra-
gility fractures, such as vertebral fractures, 
were common in patients treated for PMR 
despite anti-resorptive therapy in 80%, al-
though only 10% of patients with PMR de-
veloped new fractures, with a further 37% 
already having a prior history of fragility 
fracture prior to treatment of PMR (51). In 
a retrospective study of 222 patients with 
PMR, Mazzantini et al. reported that os-
teoporosis and fragility fractures occurred 
significantly more frequently in those who 
were treated for >2 years compared to 
those treated for <2 years (33). After ad-
justment for age and sex, fragility fractures 
were significantly associated with cumula-
tive GC dose, and osteoporosis was signifi-
cantly associated with GC treatment dura-
tion (33). 
For the management of glucocorticoid-
induced osteoporosis, all patients need an 
adequate intake of calcium and vitamin D 
either through the diet or through supple-
ments, and appropriate advice on physical 
activity and exercise. Mok et al., in a ran-
domized, placebo-controlled trial of 120 
patients receiving high-dose steroid thera-
py (>0.5 mg/kg/day of oral prednisolone or 
its equivalent for at least 6 weeks) observed 
that the group of patients who were using 
bisphosphonates (risedronate 5 mg/day) 
had significant gain in spinal bone mineral 
density (+0.7±0.3%) whereas a fall in bone 
mineral density was observed in the pla-
cebo group (−0.7±0.4%) (52).
Regarding further pharmacological treat-
ments, many local and national guidelines 
in the UK, US and France provide rec-
ommendations appropriate for the local 
healthcare setting. The American College 
of Rheumatology has recently published 
an updated, evidence-based guidelines on 
prevention and management of glucocor-
ticoid-induced osteoporosis (53). Recom-
mendations in this paper, include treating 
with calcium and vitamin D in adults at 
low fracture risk, treating with calcium and 
vitamin D plus an additional osteoporosis 
medication (oral bisphosphonate preferred) 
in adults at moderate-to-high fracture risk, 
continuing calcium plus vitamin D but 
switching from an oral bisphosphonate to 
another antifracture medication in adults in 
whom oral bisphosphonate treatment is not 
appropriate, and continuing oral bisphos-
phonate treatment or switching to another 
antifracture medication in adults who com-
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plete a planned oral bisphosphonate regi-
men but continue to receive GC treatment. 
The commonly-utilised World Health Or-
ganisation FRAX tool now allows clini-
cians to account for glucocorticoid therapy 
in estimating fracture risk, but it needs to 
be acknowledged that the fracture risk is 
dose-dependent and that further adjustment 
to risk estimates may be appropriate to ac-
count for the level of glucocorticoid dose, 
since patients receiving greater than 7.5 mg 
prednisolone daily are at a higher risk of 
fracture than those receiving less than 7.5 
mg daily.
In addition GC therapy is a well-document-
ed risk factor for avascular necrosis, which 
may occur in various sites including the 
femoral head (54). Because avascular ne-
crosis is relatively rare compared to fragil-
ity fracture, and may not be well-recorded 
in population-based datasets, the precise 
risk of avascular necrosis in PMR is un-
known. However, it is important because it 
may require surgical intervention.
Metabolic comorbidity in polymyalgia 
rheumatica
Long-term GC in the context of PMR is 
associated with weight gain in almost all 
patients. In 129 patients with PMR, 43.5% 
gained >5% body weight by 12 months 
(32). In addition systemic GC have a more 
immediate adverse effect on glucose toler-
ance and may induce hyperglycaemia and 
diabetes mellitus (34, 49). Gabriel et al. 
reported that the risk ratio of diabetes was 
2.0 in males and 2.2 in females with PMR 
when compared with age- and sex-matched 
controls from the same population (49). A 
meta-analysis revealed that metabolic dis-
ease is one of the most frequently-reported 
adverse events in PMR (50). The precise 
risk of diabetes in GC-treated PMR is un-
clear.
As well as increasing the risk of diabetes, 
GC-induced weight gain can exacerbate 
many other comorbidities and result in a 
significant health burden including exer-
tional dyspnoea, joint pains, acid reflux, 
hypertension, psychological distress and 
all the other potential consequences of 
obesity. GC-induced weight gain can lead 
to increased symptoms from osteoarthritis 
of the weight-bearing joints. This can be 
particularly problematic because the anti-
inflammatory action of GC may also allevi-
ate some of the symptoms of osteoarthritis, 
leading to an increase in joint pains on GC 
tapering that may be mistaken for a flare 
of PMR and prompting escalation of GC 
therapy.
Ocular comorbidity in polymyalgia 
rheumatica
Cataract is common in older people. Long-
term GC therapy can lead to acceleration of 
cataract formation (55), particularly poste-
rior subcapsular cataract. Especially in pa-
tients with pre-existing visual impairment 
from other age-related conditions (such as 
macular degeneration), accelerated cataract 
can severely impair patient quality of life. 
Cataract may require surgical treatment to 
avoid progression to blindness. There is 
some evidence that patients with GC-treat-
ed PMR are at increased risk of cataract 
(56) although the research base does not 
enable us to make a precise estimate of the 
degree of elevation of cataract risk in PMR 
compared to the general population.
Iatrogenic adrenal suppression
Patients with untreated PMR may have 
impaired functioning of the hypothalamic-
pituitary-adrenal (HPA) axis (57-59). This 
has been suggested to be possibly due to 
their age combined with the effect of the 
systemic inflammation that accompanies 
untreated PMR. During long-term GC 
therapy, however, homeostatic mecha-
nisms cause iatrogenic suppression of cor-
tisol production by the adrenal glands. This 
adrenal suppression may persist even after 
the exogenous GC therapy has ceased. The 
result of this is that during tapering of the 
GC dose in PMR, it may take some time 
for the HPA axis to recover its former re-
sponsiveness. How this should be managed 
in clinical practice remains unclear. Pa-
tients with iatrogenic adrenal suppression 
receiving subphysiological doses of GC 
may require short-term rescue GC therapy 
in the event of severe intercurrent illness or 
major surgery.
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Psychological comorbidity
Psychological sequelae are common fol-
lowing the diagnosis of any chronic illness. 
Compounding this, GC therapy itself may 
have psychological adverse effects rang-
ing from anxiety/irritability to significant 
depression or, rarely, frank psychosis. 
The reported prevalence of depression in 
PMR varies from 2 to 29% depending on 
the method of ascertainment of depression 
used (32, 60-62). 
The sample size of those studies was rela-
tively small and were based on secondary 
care settings, thus limiting generalisability. 
In a recent cross-sectional study in primary 
care settings in UK, Vivekanantham et al. 
reported a higher prevalence of current 
depressive symptoms among primary care 
PMR patients in comparison with the gen-
eral older adult population (63). Risk fac-
tors for depression in this study included 
female sex, younger age, and presence of 
glucocorticoid-related comorbidities; in 
multivariable analysis, only diabetes re-
mained significantly associated with symp-
toms of depression (63).
n	 DISCUSSION  
AND CONCLUSIONS
Clinical practice guidelines recommend as-
sessment for comorbidity in PMR, with a 
particular focus on those comorbidities that 
are relevant to decisions about GC dose 
and duration. In this review, we focus on 
cardiovascular disease, osteoporosis, meta-
bolic disease/diabetes, cataract and depres-
sion, and the management of iatrogenic 
adrenal suppression in the context of taper-
ing long-term GC therapy. Standardised 
reporting forms have been suggested for 
assessment of comorbidity in patients with 
inflammatory rheumatic diseases in daily 
clinical practice and would also appear rel-
evant to the clinical care of patients with 
PMR (12). 
PMR symptoms may also herald the onset 
of other serious diseases such as GCA, RA 
or malignancy. The relatively high rate of 
diagnosis of these other diseases during the 
first year of treatment for PMR suggests 
that there should be a low threshold for in-
vestigation if the disease does not appear to 
be following its usual course. Patients with 
a dual diagnosis of PMR and GCA are gen-
erally treated with high-dose GC because 
higher doses of GC are required for GCA 
than for PMR. Patients with polymyalgic 
symptoms who subsequently develop clini-
cal features of RA may often respond well 
to a combination of standard RA therapy 
together with low-dose GC therapy until 
the inflammation comes under effective 
control; this presentation of RA is howev-
er sufficiently uncommon that large-scale 
population data on this are lacking. How or 
whether to combine ongoing GC therapy 
for PMR with treatment of a newly-diag-
nosed cancer remains unclear, and deci-
sions need to be taken on an individualized 
basis depending on the type of cancer and 
the patient’s symptom burden.
Accurate estimates of risk and prognosis 
of comorbidities accompanying PMR are 
difficult to obtain from traditional trials 
and disease cohorts because of limita-
tions of sample size and the observation 
that many important GC-related adverse 
events, such as fracture, tend to accumu-
late over many years of GC therapy. In-
creased availability of routinely-collected 
clinical data, particularly with linkage 
across multiple datasets, may help to de-
rive more precise estimates as to the prog-
nosis of patients with PMR and comorbid 
conditions and to help inform how we 
should screen for, monitor and manage 
these in routine clinical practice.
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